Skip to content

Study · Observational study · n = 1,199 · 2020

11 results

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses.

Pratley RE, Aroda VR, Catarig AM, Lingvay I, Lüdemann J, Yildirim E, Viljoen A

BMJ open16 Nov 2020Cited by 18 (Europe PMC)

PMID33199417 (opens in a new tab)PMCIDPMC7670946 (opens in a new tab)DOI10.1136/bmjopen-2020-037883 (opens in a new tab)PepBankPUB-33199417
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study11

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In diabetes subgroups, semaglutide generally reduced HbA1c more than dulaglutide, with exceptions in low-dose glycemic-control comparisons.

    In plain wordsIn diabetes subgroups, semaglutide generally reduced average blood sugar more than dulaglutide, with exceptions in low-dose comparisons.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction across subgroups
    Study

    n = 1,199

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5 mg or 1.0 mg · subcutaneous · 40 weeksAs given in this study (human).

    Measurements

    HbA1c treatment difference
    −0.7 to −0.22 percentage points
    semaglutide versus dulaglutide across subgroup comparisons

    Source sentences

    Summary
    HbA1c and BW reductions (estimated treatment difference ranges: -0.22 to -0.70%-point; -1.76 to -3.84 kg) and proportion of subjects achieving HbA1c targets and weight-loss responses were statistically significantly greater for the majority of comparisons of semaglutide versus…
    4 context sentences
    Summary · context
    and, excepting glycaemic control within the low-dose comparison in HbA1c subgroups, this was irrespective of subgroup or dose comparison.
    Summary · context
    This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide.
    Summary · context
    Analyses by baseline age (5-10, >10 years), HbA1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (2).
    Summary · context
    Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly.
  2. 02HumanObservational studyEfficacy outcome

    In diabetes subgroups, dulaglutide generally reduced HbA1c less than semaglutide, with exceptions in low-dose glycemic-control comparisons.

    In plain wordsIn diabetes subgroups, dulaglutide generally reduced average blood sugar less than semaglutide, with exceptions in low-dose comparisons.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHbA1c reduction across subgroups
    Study

    n = 1,199

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg or 1.5 mg · subcutaneous · 40 weeksAs given in this study (human).

    Measurements

    HbA1c treatment difference, semaglutide versus dulaglutide
    −0.7 to −0.22 percentage points
    across subgroup comparisons

    Source sentences

    Summary
    HbA1c and BW reductions (estimated treatment difference ranges: -0.22 to -0.70%-point; -1.76 to -3.84 kg) and proportion of subjects achieving HbA1c targets and weight-loss responses were statistically significantly greater for the majority of comparisons of semaglutide versus…
    4 context sentences
    Summary · context
    and, excepting glycaemic control within the low-dose comparison in HbA1c subgroups, this was irrespective of subgroup or dose comparison.
    Summary · context
    This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide.
    Summary · context
    Analyses by baseline age (5-10, >10 years), HbA1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (2).
    Summary · context
    Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly.
  3. 03HumanObservational studyEfficacy outcome

    In diabetes subgroups, semaglutide generally reduced body weight more than dulaglutide across subgroup and dose comparisons.

    In plain wordsIn diabetes subgroups, semaglutide generally reduced weight more than dulaglutide across subgroup and dose comparisons.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight reduction across subgroups
    Study

    n = 1,199

    Comparator
    Dulaglutide
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg or 1.0 mg · subcutaneous · 40 weeksAs given in this study (human).

    Measurements

    Body weight treatment difference
    −3.84 to −1.76 kg
    semaglutide versus dulaglutide across subgroup comparisons

    Source sentences

    Summary
    HbA1c and BW reductions (estimated treatment difference ranges: -0.22 to -0.70%-point; -1.76 to -3.84 kg) and proportion of subjects achieving HbA1c targets and weight-loss responses were statistically significantly greater for the majority of comparisons of semaglutide versus…
    4 context sentences
    Summary · context
    and, excepting glycaemic control within the low-dose comparison in HbA1c subgroups, this was irrespective of subgroup or dose comparison.
    Summary · context
    This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide.
    Summary · context
    Analyses by baseline age (5-10, >10 years), HbA1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (2).
    Summary · context
    Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly.
  4. 04HumanObservational studyEfficacy outcome

    In diabetes subgroups, dulaglutide generally reduced body weight less than semaglutide across subgroup and dose comparisons.

    In plain wordsIn diabetes subgroups, dulaglutide generally reduced weight less than semaglutide across subgroup and dose comparisons.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseBody weight reduction across subgroups
    Study

    n = 1,199

    Comparator
    Semaglutide
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.75 mg or 1.5 mg · subcutaneous · 40 weeksAs given in this study (human).

    Measurements

    Body weight treatment difference, semaglutide versus dulaglutide
    −3.84 to −1.76 kg
    across subgroup comparisons

    Source sentences

    Summary
    HbA1c and BW reductions (estimated treatment difference ranges: -0.22 to -0.70%-point; -1.76 to -3.84 kg) and proportion of subjects achieving HbA1c targets and weight-loss responses were statistically significantly greater for the majority of comparisons of semaglutide versus…
    4 context sentences
    Summary · context
    and, excepting glycaemic control within the low-dose comparison in HbA1c subgroups, this was irrespective of subgroup or dose comparison.
    Summary · context
    This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide.
    Summary · context
    Analyses by baseline age (5-10, >10 years), HbA1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (2).
    Summary · context
    Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly.
  5. 05HumanObservational studyEfficacy outcome

    In diabetes subgroups, semaglutide generally produced greater HbA1c target achievement than dulaglutide, with low-dose glycemic-control exceptions.

    In plain wordsIn diabetes subgroups, more patients generally reached blood sugar targets with semaglutide than dulaglutide, with low-dose exceptions.

    Peptide
    Semaglutide
    Outcome
    IncreaseHbA1c target achievement
    Study

    n = 1,199

    Comparator
    Dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5 mg or 1.0 mg · subcutaneous · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    HbA1c and BW reductions (estimated treatment difference ranges: -0.22 to -0.70%-point; -1.76 to -3.84 kg) and proportion of subjects achieving HbA1c targets and weight-loss responses were statistically significantly greater for the majority of comparisons of semaglutide versus…
    4 context sentences
    Summary · context
    and, excepting glycaemic control within the low-dose comparison in HbA1c subgroups, this was irrespective of subgroup or dose comparison.
    Summary · context
    This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide.
    Summary · context
    Analyses by baseline age (5-10, >10 years), HbA1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (2).
    Summary · context
    Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly.
  6. 06HumanObservational studyEfficacy outcome

    In diabetes subgroups, dulaglutide generally produced lower HbA1c target achievement than semaglutide, with low-dose glycemic-control exceptions.

    In plain wordsIn diabetes subgroups, fewer patients generally reached blood sugar targets with dulaglutide than semaglutide, with low-dose exceptions.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c target achievement
    Study

    n = 1,199

    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg or 1.5 mg · subcutaneous · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    HbA1c and BW reductions (estimated treatment difference ranges: -0.22 to -0.70%-point; -1.76 to -3.84 kg) and proportion of subjects achieving HbA1c targets and weight-loss responses were statistically significantly greater for the majority of comparisons of semaglutide versus…
    4 context sentences
    Summary · context
    and, excepting glycaemic control within the low-dose comparison in HbA1c subgroups, this was irrespective of subgroup or dose comparison.
    Summary · context
    This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide.
    Summary · context
    Analyses by baseline age (5-10, >10 years), HbA1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (2).
    Summary · context
    Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly.
  7. 07HumanObservational studyEfficacy outcome

    In diabetes subgroups, semaglutide generally produced greater weight loss response rates than dulaglutide.

    In plain wordsIn diabetes subgroups, more patients generally reached weight loss targets with semaglutide than dulaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss response
    Study

    n = 1,199

    Comparator
    Dulaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg or 1.0 mg · subcutaneous · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    HbA1c and BW reductions (estimated treatment difference ranges: -0.22 to -0.70%-point; -1.76 to -3.84 kg) and proportion of subjects achieving HbA1c targets and weight-loss responses were statistically significantly greater for the majority of comparisons of semaglutide versus…
    3 context sentences
    Summary · context
    This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide.
    Summary · context
    Analyses by baseline age (5-10, >10 years), HbA1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (2).
    Summary · context
    Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly.
  8. 08HumanObservational studyEfficacy outcome

    In diabetes subgroups, dulaglutide generally produced lower weight loss response rates than semaglutide.

    In plain wordsIn diabetes subgroups, fewer patients generally reached weight loss targets with dulaglutide than semaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight loss response
    Study

    n = 1,199

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.75 mg or 1.5 mg · subcutaneous · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    HbA1c and BW reductions (estimated treatment difference ranges: -0.22 to -0.70%-point; -1.76 to -3.84 kg) and proportion of subjects achieving HbA1c targets and weight-loss responses were statistically significantly greater for the majority of comparisons of semaglutide versus…
    3 context sentences
    Summary · context
    This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide.
    Summary · context
    Analyses by baseline age (5-10, >10 years), HbA1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (2).
    Summary · context
    Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly.
  9. 09HumanObservational studySafety outcome

    In diabetes patients receiving semaglutide, gastrointestinal adverse events decreased with increasing BMI.

    In plain wordsAmong people with diabetes receiving semaglutide, digestive adverse events were less frequent at higher body mass index.

    Peptide
    Semaglutide
    Outcome
    DecreaseGastrointestinal adverse events by BMI
    Study

    n: not reported in source

    Comparator
    Lower BMI among semaglutide recipients
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.5 mg or 1.0 mg · subcutaneous · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal adverse events, the most common with both treatments, were reported by more women than men and, with semaglutide, decreased with increasing BMI.
    3 context sentences
    Summary · context
    This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide.
    Summary · context
    Analyses by baseline age (5-10, >10 years), HbA1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (2).
    Summary · context
    Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 10HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In adults with type 2 diabetes, gastrointestinal adverse events were reported by more women than men across semaglutide and dulaglutide treatment.

    In plain wordsIn people with type 2 diabetes treated with semaglutide or dulaglutide, women reported more digestive side effects than men.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal adverse events by sex
    Study

    n = 1,199

    Comparator
    Men
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Gastrointestinal adverse events, the most common with both treatments, were reported by more women than men and, with semaglutide, decreased with increasing BMI.
    3 context sentences
    Summary · context
    This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide.
    Summary · context
    Analyses by baseline age (5-10, >10 years), HbA1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (2).
    Summary · context
    Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome

    In adults with type 2 diabetes, gastrointestinal adverse events were reported by more women than men across semaglutide and dulaglutide treatment.

    In plain wordsIn people with type 2 diabetes treated with semaglutide or dulaglutide, women reported more digestive side effects than men.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseGastrointestinal adverse events by sex
    Study

    n = 1,199

    Comparator
    Men
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Gastrointestinal adverse events, the most common with both treatments, were reported by more women than men and, with semaglutide, decreased with increasing BMI.
    3 context sentences
    Summary · context
    This post hoc analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide.
    Summary · context
    Analyses by baseline age (5-10, >10 years), HbA1c (≤7.5, >7.5-8.5, >8.5% (≤58, >58-69, >69 mmol/mol)) and body mass index (BMI) (2).
    Summary · context
    Semaglutide 0.5 mg versus dulaglutide 0.75 mg (low-dose comparison); semaglutide 1.0 mg versus dulaglutide 1.5 mg (high-dose comparison), all subcutaneously once weekly.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02648204

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Novo Nordisk A/Sn = 1,2016 Jan 2016 to 19 May 2017

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 15 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.